You have 9 free searches left this month | for more free features.

City

Nanchang (1)

Condition

Unresectable Hepatocellular Carcinoma (1)

Unresectable Intrahepatic Cholangiocarcinoma (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Hua Li (1)

Wen Li (1)

Collaborator

Intervention

d-tace (2)

camrelizumab (1)

cisplatin injection (1)

cisplatin-eluting beads (1)

gemcitabine injection (1)

haic (1)

lenvatinib (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (2)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (2)

d-tace

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)

Not yet recruiting

Unresectable Intrahepatic Cholangiocarcinoma

Camrelizumab
+4 more

(no location specified)

Feb 17, 2023

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting

Unresectable Hepatocellular Carcinoma

D-TACE
+3 more

Nanchang, Jiangxi, China

The Second Affiliated Hospital of Nanchang University

Oct 14, 2022